No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome

Blood. 2005 May 15;105(10):4148-9. doi: 10.1182/blood-2004-11-4314.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Alemtuzumab
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / adverse effects*
  • Antibodies, Neoplasm / immunology
  • Antibodies, Neoplasm / therapeutic use*
  • Clinical Trials as Topic
  • Female
  • Heart / drug effects
  • Humans
  • Immunotherapy
  • Male
  • Middle Aged
  • Mycosis Fungoides / drug therapy*
  • Mycosis Fungoides / immunology
  • Retrospective Studies
  • Sezary Syndrome / drug therapy*
  • Sezary Syndrome / immunology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Alemtuzumab